Biliary tract carcinomas: From chemotherapy to targeted therapy

Marino, Donatella; Leone, Francesco; Cavalloni, Giuliana; Cagnazzo, Celeste; Aglietta, Massimo

doi:10.1016/j.critrevonc.2012.06.006

Cited by 37 publications

(26 citation statements)

References 133 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We explored any potential explanation for this survival advantage in IHC patients despite similar PFS. In this subgroup, the median number of cycles was 6 (range, [3][4][5][6][7][8][9][10][11][12] in the P-GEMOX group and 11 (range, 2-12) in the GEMOX group, with more patients in the standard arm completing the preplanned 12-cycle treatment (10 patients in the GEMOX group vs 6 patients in the P-GEMOX group). Moreover, we could not demonstrate any significant difference in the causes of the end of treatment, occurrence of adverse events, second-line treatments, or surgery between the arms (data not shown).…”

Section: Resultsmentioning

confidence: 95%

See 1 more Smart Citation

Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti‐BIL study)

Leone

Marino

Cereda

et al. 2015

Cancer

Self Cite

121

View full text Add to dashboard Cite

BACKGROUND: Biliary tract cancer (BTC) is a rare and lethal disease with few therapeutic options. Preclinical data suggest that the epidermal growth factor receptor (EGFR) pathway could be involved in its progression. METHODS: This open-label, randomized phase 2 trial recruited chemotherapy-naive patients with advanced BTC displaying a wild-type (WT) KRAS status. Patients were randomized to gemcitabine (1000 mg/m 2 ) and oxaliplatin (100 mg/m 2 ) with (arm A) or without (arm B) panitumumab (6 mg/kg) for up to 12 cycles. The primary endpoint was progression-free survival (PFS) analyzed in an intention-to-treat fashion. RESULTS: Eighty-nine patients (45 in arm A and 44 in arm B) were enrolled between June 2010 and September 2013. After a median follow-up of 10.1 months, the median PFS was 5.3 months (95% confidence interval, 3.3-7.2 months) in arm A and 4.4 months (95% confidence interval, 2.6-6.2 months) in arm B (P 5.27). No survival differences were observed: the median overall survival was 9.9 months in arm A and 10.2 months in arm B (P 5.42). In a subgroup analysis, no differences in PFS according to the site of the primary tumor were observed; patients with intrahepatic cholangiocarcinoma treated with panitumumab may have had a survival benefit in comparison with the control group (15.1 vs 11.8 months, P 5.13). As for safety, skin toxicity was the main adverse event in arm A (80% of the patients). A higher incidence of diarrhea (55.5% vs 31.8%), mucositis (22.2% vs 13.6%), and constipation (24.4% vs 15.9%) was seen in arm A. CONCLUSIONS: These results confirm the marginal role of anti-EGFR therapy even for WT KRAS-selected BTC. Cancer 2016;122:574-81.

show abstract

Section: Resultsmentioning

confidence: 95%

“…4,5 Preclinical data have suggested the involvement of the epidermal growth factor receptor (EGFR) pathway in BTC pathogenesis. EGFR is often overexpressed in this disease, and in some cases, activating mutations have been detected.…”

Section: Introductionmentioning

confidence: 99%

Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti‐BIL study)

Leone

Marino

Cereda

et al. 2015

Cancer

Self Cite

121

View full text Add to dashboard Cite

show abstract

“…New derivatives, such as the oral fluoropyrimidine (F) S1, have been developed from 5-fluorouracil, and new classes of drugs have been introduced, such as antibodies (mabs) and kinase inhibitors (nibs) - so-called biologicals (bio). Mabs and nibs act against defined molecular targets, such as EGFR, VEGF or the RAS-MAPK pathway [12]. However, for separate analysis of a new agent subgroup, the number of trials and patients was too low in our first pooled analysis of clinical trials.…”

Section: Introductionmentioning

confidence: 99%

Chemotherapy and Targeted Therapy in Advanced Biliary Tract Carcinoma: A Pooled Analysis of Clinical Trials

Eckel

Schmid

2014

Chemotherapy

View full text Add to dashboard Cite

Background: In biliary tract cancer, gemcitabine platinum (GP) doublet palliative chemotherapy is the current standard treatment. The aim of this study was to analyze recent trials, even those small and nonrandomized, and identify superior new regimens. Methods: Trials published in English between January 2000 and January 2014 were analyzed, as well as ASCO abstracts from 2010 to 2013. Results: In total, 161 trials comprising 6,337 patients were analyzed. The pooled results of standard therapy GP (no fluoropyrimidine, F, or other drug) were as follows: the median response rate (RR), tumor control rate (TCR), time to tumor progression (TTP) and overall survival (OS) were 25.9 and 63.5%, and 5.3 and 9.5 months, respectively. GFP triplets as well as G-based chemotherapy plus targeted therapy were significantly superior to GP concerning tumor control (TCR, TTP) and OS, with no difference in RR. Conclusion: Triplet combinations of GFP as well as G-based chemotherapy with (predominantly EGFR) targeted therapy are most effective concerning tumor control and survival.

show abstract

“…Este fenómeno probablemente es debido a su baja incidencia en la mayoría de los países desarrollados, por lo cual su estudio ha sido relegado a un plano secundario [6][7][8] . Lamentablemente, muchos trabajos en el área de la biología molecular incluyen erróneamente además del cáncer vesicular, a cánceres de los conductos biliares e, inclusive, de los conductos hepáticos, como un solo grupo de tumores, lo cual disminuye y restringe el valor de las observaciones 9,10 . Los trabajos existentes en esta área corresponden a pequeñas casuísticas o son producto de recopilaciones de casos de distintas instituciones y, a veces, de distintos países, lo que también le resta validez a los resultados.…”

unclassified

¿Es posible utilizar las muestras de colecistectomías con cáncer en investigación?: Calidad del ADN de muestras obtenidas del sistema público y privado de salud

Roa¹,

Toro

Sanchez

et al. 2013

Rev. méd. Chile

View full text Add to dashboard Cite

show abstract

Biliary tract carcinomas: From chemotherapy to targeted therapy

Cited by 37 publications

References 133 publications

Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti‐BIL study)

Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti‐BIL study)

Chemotherapy and Targeted Therapy in Advanced Biliary Tract Carcinoma: A Pooled Analysis of Clinical Trials

¿Es posible utilizar las muestras de colecistectomías con cáncer en investigación?: Calidad del ADN de muestras obtenidas del sistema público y privado de salud

Contact Info

Product

Resources

About